Sermorelin vs CJC-1295 No DAC (Mod GRF 1-29)
GHRH Analog (GRF 1-29) · Modified GHRH Analog
Here is how these two compounds compare, based on published research, not marketing claims.
Sermorelin
The original GHRH analog, with FDA-approval history and the deepest research base in its class.
CJC-1295 No DAC
A modified GHRH fragment sold under the CJC-1295 name, but pharmacologically closer to Sermorelin than to CJC-1295 with DAC.
Sermorelin
328 studies
20 human trials
Not FDA-Approved
CJC-1295 No DAC
662 studies
18 human trials
Not FDA-Approved
What it does
Sermorelin
Copies the working portion of the body's natural growth hormone signal directly, with no modifications added: just the first 29 amino acids of GHRH out of 44 in the full molecule. The original peptide in this class, and still the closest thing to what the brain actually produces. Half-life is short by design, on the order of 10 to 15 minutes, the same as native GHRH.
CJC-1295 No DAC
Tells the pituitary gland to release growth hormone in pulses that match the body's natural rhythm. Cleared from the bloodstream within hours, requiring more frequent administration than long-acting alternatives.
How it works
Sermorelin
A lab-made copy of the first 29 amino acids of the body's natural growth hormone signal. It matches what the body already produces, which is why people call it the 'closest to natural' option.
CJC-1295 No DAC
A lab-modified version of the body's natural growth hormone signal (GHRH 1-29), with four amino acid substitutions that make it more stable. Functionally very similar to Sermorelin; the modifications extend its active window modestly but do not fundamentally change the mechanism.
How often
Sermorelin
In studies and historical clinical use as Geref, sermorelin was given as a daily subcutaneous injection, typically in the evening, which clinical literature describes as aligned with the body's natural overnight growth hormone pulse. The active window is brief, roughly ten minutes.
CJC-1295 No DAC
In studies of modified GHRH(1-29), the compound was given as a daily subcutaneous injection, typically in the evening, which clinical literature describes as aligned with the body's natural overnight growth hormone pulse. The active window is roughly thirty minutes, longer than sermorelin's but far shorter than CJC-1295 with DAC's.
How strong
Sermorelin
Mild. A modest increase over the body's natural growth hormone release, not an override.
CJC-1295 No DAC
Comparable to Sermorelin. A small step up in pulse durability, not a category change.
Main tradeoff
Sermorelin
Daily injections. Subtler effects. Some people plateau after several months.
CJC-1295 No DAC
Sold under the CJC-1295 name in some research-peptide channels, which creates confusion with the much longer-acting with-DAC version. The compound itself is well-characterized, but the branding is not.
Best for
Sermorelin
- Beginners to peptides
- People who want the most 'natural' approach
- Anyone prioritizing a gentle, long-term effect over peak results
CJC-1295 No DAC
- People who encountered the 'No DAC' branding through research-peptide suppliers and want to understand what they are getting
- People who want a Sermorelin-class compound with marginally longer stability
- Anyone comparing daily-injection GHRH analogs and weighing sourcing channels
How to choose
A good fit for Sermorelin
- Prioritizing a compound with former FDA approval and decades of clinical use data
- Working with a prescriber who uses established compounding pharmacy supply chains
- Research focused on the GHRH analog with the deepest published human safety record in its class
- Wanting the most conservative starting point for GHRH analog research
A good fit for CJC-1295 No DAC
- Encountered the 'No DAC' branding through research-peptide channels and want to understand what it is
- Looking for a Sermorelin-class compound with marginally longer stability per injection
- Comparing daily-injection GHRH analogs across different sourcing channels
- Tracking protocols that specifically reference 'CJC-1295 No DAC' or 'Mod GRF 1-29' by name
Consider both across time
Sermorelin and CJC-1295 No DAC are pharmacokinetically similar compounds from the same mechanism class. The meaningful differences are in regulatory history, branding clarity, and supply chain sourcing, not in pharmacology. Someone evaluating both is essentially comparing two versions of the same approach.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates Adenylyl Cyclase
- Adenylyl Cyclase connects to cAMP Signaling
- cAMP Signaling connects to GH Transcription
- GH Transcription connects to Growth Hormone Release
- Growth Hormone Release connects to IGF-1 Elevation
Sermorelin binds the GHRH receptor on the pituitary (the body's natural 'release growth hormone' signal) and tells it to fire.
CJC-1295 No DAC binds the same receptor with amino acid modifications for marginally improved stability, but the downstream cascade is the same.
Research Evidence
Sermorelin has the deeper research base: decades of clinical use, former FDA approval, and a well-characterized safety profile across pediatric and adult populations. CJC-1295 No DAC inherits some evidence from studies on modified GHRH(1-29) and from the broader CJC-1295 development program, but has no regulatory history of its own under this name.
- 1.
For research prioritizing clinical precedent and regulatory history, Sermorelin offers the deeper evidence foundation.
- 2.
For research exploring daily-injection GHRH analogs with marginally improved metabolic stability, CJC-1295 No DAC provides a modest pharmacokinetic advantage.
- 3.
For research comparing sourcing channels and branding clarity, the practical difference between these compounds is primarily in market naming, not pharmacology.
Key Limitations
- •CJC-1295 No DAC has no standalone regulatory history or Phase III data.
- •The naming convention ('CJC-1295 No DAC') creates market confusion with the pharmacologically distinct CJC-1295 with DAC.
- •Neither compound has been studied in modern Phase III trials for therapeutic GH deficiency endpoints.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Sermorelin
"Sermorelin is the safest way to boost growth hormone naturally"
Plausible but unproven
"It improves sleep quality dramatically"
Plausible but unproven
"It stopped working after a few months"
Plausible but unproven
Safety Comparison
Both compounds have favorable safety profiles consistent with GHRH analog pharmacology. Sermorelin's safety data is more extensive because of its FDA-approved history. CJC-1295 No DAC's safety is inferred primarily from its pharmacological similarity to Sermorelin and from the broader GHRH analog literature.
Sermorelin
The most extensively studied growth hormone-releasing peptide in clinical settings. Approved by the FDA as Geref for diagnostic use. Studies in children and adults have established a favorable safety profile with few serious adverse events.
CJC-1295 No DAC (Mod GRF 1-29)
Safety profile inferred from pharmacological similarity to Sermorelin and the broader GHRH analog literature. No standalone regulatory history under this name.
What the Research Suggests
Sermorelin and CJC-1295 No DAC are pharmacokinetically similar compounds from the same mechanism class. The meaningful differences are in regulatory history, branding clarity, and supply chain sourcing. Sermorelin has the stronger clinical track record. CJC-1295 No DAC offers marginal stability improvements with confusing market naming. The choice between them is primarily practical, not pharmacological.